New Approaches in Nanomedicine for Ischemic Stroke
| dc.contributor.affiliation | Universidade de Santiago de Compostela. Centro de Investigación en Química Biolóxica e Materiais Moleculares | gl |
| dc.contributor.affiliation | Universidade de Santiago de Compostela. Departamento de Física de Partículas | gl |
| dc.contributor.affiliation | Universidade de Santiago de Compostela. Departamento de Química Inorgánica | gl |
| dc.contributor.author | Correa Paz, Clara | |
| dc.contributor.author | Silva Candal, Andrés da | |
| dc.contributor.author | Polo Tobajas, Ester | |
| dc.contributor.author | Parcq, Jerome | |
| dc.contributor.author | Vivien, Denis | |
| dc.contributor.author | Maysinger, Dusica | |
| dc.contributor.author | Pelaz García, Beatriz | |
| dc.contributor.author | Campos Pérez, Francisco | |
| dc.date.accessioned | 2021-05-21T11:53:26Z | |
| dc.date.available | 2021-05-21T11:53:26Z | |
| dc.date.issued | 2021 | |
| dc.description.abstract | Ischemic stroke, caused by the interruption of blood flow to the brain and subsequent neuronal death, represents one of the main causes of disability in developed countries. Therapeutic methods such as recanalization approaches, neuroprotective drugs, or recovery strategies have been widely developed to improve the patient’s outcome; however, important limitations such as a narrow therapeutic window, the ability to reach brain targets, or drug side effects constitute some of the main aspects that limit the clinical applicability of the current treatments. Nanotechnology has emerged as a promising tool to overcome many of these drug limitations and improve the efficacy of treatments for neurological diseases such as stroke. The use of nanoparticles as a contrast agent or as drug carriers to a specific target are some of the most common approaches developed in nanomedicine for stroke. Throughout this review, we have summarized our experience of using nanotechnology tools for the study of stroke and the search for novel therapies | gl |
| dc.description.peerreviewed | SI | gl |
| dc.description.sponsorship | This project was supported by the FRQS, ISCIII (AC19/00031 and AC20/00041), and ANR under the framework of EuroNanoMed III_2020 (PLATMED_project); the European Union program FEDER and the European Regional Development Fund–ERDF; and the Xunta de Galicia (IN607D2020/03 and ED431G2019/03). E.P. and B.P acknowledge the AEI grants (PID2019-111218RB-I00 and RyC-2017-23457). Finally, F.C. thanks the ISCIII and Miguel Servet program (CPII19/00020) | gl |
| dc.identifier.citation | Pharmaceutics 2021, 13(5), 757; https://doi.org/10.3390/pharmaceutics13050757 | gl |
| dc.identifier.doi | 10.3390/pharmaceutics13050757 | |
| dc.identifier.essn | 1999-4923 | |
| dc.identifier.uri | http://hdl.handle.net/10347/26254 | |
| dc.language.iso | eng | gl |
| dc.publisher | MDPI | gl |
| dc.relation.projectID | info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/RYC-2017-23457/ES | |
| dc.relation.publisherversion | https://doi.org/10.3390/pharmaceutics13050757 | gl |
| dc.rights | © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/) | gl |
| dc.rights | Atribución 4.0 Internacional | |
| dc.rights.accessRights | open access | gl |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
| dc.subject | Cell tracking | gl |
| dc.subject | Diagnosis | gl |
| dc.subject | Drug carriers | gl |
| dc.subject | Drug control release | gl |
| dc.subject | Nanomedicine | gl |
| dc.subject | Neuroprotection | gl |
| dc.subject | Recovery | gl |
| dc.subject | Stroke | gl |
| dc.subject | Tissue plasminogen activator | gl |
| dc.title | New Approaches in Nanomedicine for Ischemic Stroke | gl |
| dc.type | journal article | gl |
| dc.type.hasVersion | VoR | gl |
| dspace.entity.type | Publication | |
| relation.isAuthorOfPublication | 8b9beb32-7cfc-4c41-871e-f0960dcb60e3 | |
| relation.isAuthorOfPublication | ae6cfd5f-90ba-47e5-9d34-20c3361b7df3 | |
| relation.isAuthorOfPublication.latestForDiscovery | 8b9beb32-7cfc-4c41-871e-f0960dcb60e3 |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- 2021_pharmaceutics_correa_new.pdf
- Size:
- 6.26 MB
- Format:
- Adobe Portable Document Format
- Description: